(Total Views: 483)
Posted On: 12/19/2020 12:26:42 PM
Post# of 36564
GNBT FB page post:
Generex, through NuGenerex Immuno-Oncology, aims to provide long-term vaccine solutions to infectious diseases including #COVID19. In fact, our vaccine platform demonstrated long-term (~80-month) effectiveness and safety in low HER2 expressing and triple-negative #breastcancer in our prior clinical trial. https://bit.ly/3g51QMR
#COVID19 #biotech #coronavirusvaccine #sarscov2 #immunology #immunotherapy #tcells #biotechnology #clinicaltrial #Iikeypeptide
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
LINK.SPRINGER.COM
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
AE37 and GP2 are HER2
Generex, through NuGenerex Immuno-Oncology, aims to provide long-term vaccine solutions to infectious diseases including #COVID19. In fact, our vaccine platform demonstrated long-term (~80-month) effectiveness and safety in low HER2 expressing and triple-negative #breastcancer in our prior clinical trial. https://bit.ly/3g51QMR
#COVID19 #biotech #coronavirusvaccine #sarscov2 #immunology #immunotherapy #tcells #biotechnology #clinicaltrial #Iikeypeptide
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
LINK.SPRINGER.COM
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
AE37 and GP2 are HER2
(1)
(0)
